Protalix Biotherapeutics, Inc.
(NYSE Amex Equities : PLX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Health Services » Servicestothe Health Industry
LHLaboratory Corp. of America Holdings -0.46%176.932.4%$98.11m
DGXQuest Diagnostics, Inc. -0.51%106.564.2%$58.85m
SRCLStericycle, Inc. -0.96%63.286.3%$32.57m
SYNHSyneos Health, Inc. 0.03%63.880.0%$31.77m
RCMR1 RCM, Inc. -0.81%13.420.0%$15.54m
HCSGHealthcare Services Group, Inc. 0.06%27.186.7%$14.96m
IDXGInterpace Diagnostics Group, Inc. 5.56%8.35240.9%$3.53m
NRCNational Research Corp. 1.15%67.580.0%$2.04m
AMEHApollo Medical Holdings, Inc. 2.10%18.950.0%$1.87m
PLXProtalix Biotherapeutics, Inc. -1.22%3.5956.8%$0.80m
BASIBioanalytical Systems, Inc. 12.43%6.150.3%$0.50m
PMDPsychemedics Corp. -0.19%10.600.7%$0.26m

Company Profile

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.